Gland Pharma Limited has scheduled one-on-one meetings with analysts and institutional investors for August 26 and 27, 2026. The engagements are part of the company’s routine investor relations activities.

Meeting Schedule

The company notified stock exchanges of the schedule pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meetings will involve key financial institutions and fund managers.

Compliance Details

Sampath Kumar Pallerlamudi, Company Secretary and Compliance Officer, signed the intimation on August 23, 2026. The company noted that the schedule is subject to change due to exigencies on the part of the investor, analyst, or the company.

Gland Pharma reported a robust start to FY27, with consolidated revenue from operations rising 20% year-on-year to ₹18,003 million in the quarter ended June 30, 2026. Profit after tax (PAT) surged 47% to ₹3,170 million, driven by strong demand in its Contract Development and Manufacturing Operations (CDMO) segment and significant volume expansion in key markets like the United States. The company’s EBITDA margin expanded to 27% from 24% in the corresponding quarter of the previous year, reflecting improved operational efficiency. These results were formally communicated to investors through newspaper advertisements in English and Telugu, as mandated by regulatory guidelines.

The Board of Directors, meeting on August 10, 2026, approved the unaudited standalone and consolidated financial results pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Deloitte Haskins & Sells, the statutory auditors, issued an unmodified limited review report on the financial statements prepared in accordance with Ind AS 34. In compliance with Regulation 47 of the same regulations, Gland Pharma notified stakeholders that the results are accessible via a Quick Response (QR) code published alongside the announcement. The documents are also available on the company’s website and the platforms of BSE Limited and National Stock Exchange of India Limited.

Consolidated Financial Performance

Gland Pharma’s top-line growth was supported by equal contributions from its CDMO and B2B businesses, each accounting for 50% of total revenue. The CDMO segment grew 20% YoY to ₹8,915 million, while B2B revenue increased 19% to ₹9,088 million. Adjusted EBITDA, which excludes employee stock option compensation expenses, rose 37% to ₹5,102 million, with an adjusted margin of 28%. Management highlighted that constant currency growth stood at 15%, excluding forex impacts.

Market and Segment Highlights

The United States remained the largest market, contributing 54% of total revenue with a 32% YoY increase to ₹9,810 million. Growth was fueled by recent product launches, including Dalbavancin and Multi-Vitamin, and volume expansion in existing products such as Enoxaparin and Heparin. Europe saw an 11% revenue rise to ₹4,488 million, driven by CDMO products and improving momentum across commercial activities. Conversely, Other Core Markets (Canada, Australia, New Zealand) declined 28% to ₹534 million due to volume drops in existing products.

Research and development expenses stood at ₹772 million, representing 4% of consolidated revenue. The company launched four new molecules in the USA during the quarter. Regulatory progress included three new Abbreviated New Drug Application (ANDA) filings and seven approvals, bringing the cumulative US ANDA portfolio to 389 filings (342 approved, 47 pending).

Strategic Partnerships and Pipeline

Gland Pharma continues to strengthen its complex injectables pipeline, with six products already launched and three more awaiting approval. Fifteen products are currently in co-development, including seven 505(b)(2) applications and eight ANDAs, with commercialization expected to begin in FY28. The company also filed 21 Ready-to-Use (RTU) infusion bag products, receiving approval for 18 so far; this portfolio addresses an estimated $644 million opportunity in the US market.

Strategic collaborations include a long-term partnership with Neuland Laboratories for sterile API manufacturing of microparticle depot products and an in-licensing agreement with a China-based developer for a niche liposomal product targeting US and European markets. Additionally, a CDMO partnership with a global pharmaceutical company holds an annualized revenue potential of $90–100 million, with revenues expected to commence from calendar year 2029. This agreement covers 55 SKUs across oncology and non-oncology products, with technology transfer activities planned for completion within two years.

European Operations and Capacity Expansion

Cenexi, the company’s European subsidiary, reported revenue of €48 million with an EBITDA of €2 million. Despite disruptions from the summer heat wave in Europe, the Fontenay facility delivered good performance benefiting from the ramp-up of a new ampoule line. During the summer shutdown, the company will discontinue an older ampoule line and replace it with a high-capacity line expected to enter production in early 2027, adding approximately 30 million ampoules of annual capacity. At the Hérouville facility, activity levels continue to increase steadily, supported by higher volumes from two products successfully launched in 2025.

What the Numbers Show

The divergence between consolidated PAT growth (47%) and revenue growth (20%) highlights significant operating leverage achieved through scale. While gross profit margins remained stable at 65%, the expansion in EBITDA margins from 24% to 27% indicates effective cost management despite rising employee benefits expenses (up to ₹4,440 million from ₹4,080 million YoY). The strong cash position, with net cash at ₹32,939 million as of June 2026, provides ample liquidity to fund ongoing capital expenditures of ₹1,132 million in Q1FY27 and future pipeline developments. Management noted that the base business grew by 24%, with the US market growing 32%, underscoring the resilience of the core portfolio alongside new strategic wins.